McKesson (MCK) delivered its latest quarterly results, reporting a 23% rise in revenue, a 15% higher dividend, and an upward revision to its full-year outlook. These factors have attracted significant institutional buying.

See our latest analysis for McKesson.

It is no surprise that McKesson's latest results have turned heads, as ongoing institutional buying and robust fundamentals have built real momentum behind the stock. Over the last twelve months, the company has delivered a 58% total shareholder return. This reinforces its reputation for consistent long-term outperformance and signals continued investor confidence in its outlook.

If McKesson’s recent run and investor interest have you thinking about healthcare leaders, you can also explore See the full list for free.

With McKesson shares up more than 36% this year and trading near all-time highs, the big question is whether this rally has more room to run or if the market is already pricing in future earnings growth.

McKesson's latest fair value estimate gives it an edge over the last closing price of $758.70, setting the stage for a surprising narrative catalyst that is fueling analyst expectations.

Investments in digitization, automation, and advanced analytics across distribution centers and logistics (e.g., automated picking systems, AI, robotics) are enhancing operational efficiency, driving measurable reductions in operating expenses and supporting long-term net margin improvement.

Read the complete narrative.

How does McKesson get analysts to believe in a much higher valuation? The secret is in bold predictions around margin expansion, cost cuts, and future revenue acceleration. Discover which financial levers are driving these lofty expectations and find out what is behind the consensus price target.

Result: Fair Value of $793.21 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent regulatory scrutiny on drug pricing and growing industry consolidation could put pressure on McKesson’s margins and disrupt optimistic forecasts.

Find out about the key risks to this McKesson narrative.

If you see the facts differently or want a hands-on approach, you can quickly build and test your own investment narrative in just a few minutes. Do it your way

A great starting point for your McKesson research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Smart investors do not wait on just one stock. If you want to boost your portfolio, hand-pick opportunities from our favorite strategy screens below before they get snapped up.

Target higher yields and secure steady income by reviewing 3%;elm:context_link;itc:0;sec:content-canvas\\" class=\\"link \\">these 19 dividend stocks with yields > 3% with payouts that can support your financial goals.

Capitalize on AI breakthroughs by uncovering tomorrow’s leaders with these 24 AI penny stocks and see how innovative companies are set to shape the next decade.

Get ahead of the market by acting on value signals in these 909 undervalued stocks based on cash flows, highlighting stocks currently trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include MCK.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com